Leadership

Management

Dr. Faz Chowdhury
Chief Executive Officer

Dr. Chowdhury has served as CEO and chair of the board of Nemaura Medical since formation in December 2013.  He is sole inventor on more than 50 granted and pending patents across over 15 technology platforms within the medical device and pharmaceutical sectors. He has authored Textbook Chapters on Nano-biosciences for Wiley and Elsevier, and serves on the Board of Medilink East Midlands, UK. Dr. Chowdhury trained as a pharmaceutical scientist, and holds a Masters in Microsystems and Nanotechnology from Cranfield University, UK, and Doctorate from the University of Oxford on nano-drug delivery.

Dr. Faz Chowdhury trained as a pharmaceutical scientist, and holds a Masters in Microsystems and Nanotechnology from Cranfield University, UK, and Doctorate from the University of Oxford on nano-drug delivery. He has over 18 years experience in product development, manufacturing, and technical and corporate management.

Iain Anderson
Chief Finance Officer

Mr. Anderson has served as CFO of Nemaura Medical since December 2016. He qualified as a Chartered Certified Accountant in 1992 whilst working for Touche Ross (now Deloitte), and has worked in industry for more than 20 years with a diverse range of companies, including subsidiaries of publicly-owned corporations such as Hitachi, TriMas Corporation, Precision Castparts Corporation and Hospira Inc. Mr. Anderson received an MBA from Loughborough University in 1999.

Iain Anderson qualified as a Chartered Certified Accountant in 1992 whilst working for Touche Ross (now Deloitte) and received an MBA from Loughborough University in 1999.

Mr. Bashir Timol
Director of Strategy and Corporate Development

Mr. Timol has served as member of the board of Nemaura Medical since formation in December 2013. He has co-founded, managed and funded several biotech and life science companies, and led the investment  consortium that provided capital for the initial two funding rounds for Nemaura Medical. Mr. Timol obtained his Bachelor of Arts degree in Economics from the University of Central Lancashire, UK.

Bashir is responsible for financial business development and corporate strategies. He has over 10 years’ track record as an entrepreneur and angel investor with substantial stakes in management consultancies, pharmaceuticals firms, and restaurant franchises. Prior directorship roles include strategic support, corporate fundraising and overseeing key management Planning.

Professor Karrar Khan
Director of Product Development

Professor Karrar Khan has over 35 years’ experience of drug discovery, pharmaceutical development, registration and managing pharmaceutical scientists. His experience includes 20 years as Head of Pharmaceutical Development for Boots Pharmaceuticals and Knoll and two years as Director for OSI where he managed their pharmaceutical development, analytical operations and DMPK. His expertise range from development for phase 1 to phase 3- 4 and significant experience of bringing prescription and OTC products to market on a global level (and has contributed to the registration and launch of over 60 pharmaceutical products). He is a Qualified person under the EC quality assurance directive.

Professor Khan has over 35 years’ experience of drug discovery, pharmaceutical development, registration and managing pharmaceutical scientists. His experience includes 20 years as Head of Pharmaceutical Development for Boots Pharmaceuticals and Knoll and two years as Director for OSI where he managed their pharmaceutical development, analytical operations and DMPK.

David Scott
Director of Commercial Development and Licensing

David Scott is a trained chemist with over 35 years’ experience in the Pharmaceutical Industry spanning deal brokering, marketing, strategic planning, finance, business development and acquisitions. He is a skilled negotiator who has closed a number of major deals for inward and outward licensing for pharmaceutical products, delivery systems and technologies. He has also provided licensing training for a number of multinational pharma companies and training organisations and has published widely, (he is the author of the best-selling report, “Scrip’s Practical Guide to Pharmaceutical Licensing”). David is also an accredited “Certified Licensing Professional”.

David Scott is a trained chemist with over 35 years’ experience in the Pharmaceutical Industry spanning deal brokering, marketing, strategic planning, finance, business development and acquisitions. He is a skilled negotiator who has closed a number of major deals for inward and outward licensing for pharmaceutical products, delivery systems and technologies.

Dr Richard Toon
Technical and Business Development Manager

Dr. Richard Toon is a chartered chemist who originally trained as a synthetic chemist and more recently trained in law. He has over 20 years of experience within pharmaceutical drug development including a number of years supervising ‘blue skies’ research projects for potential commercial exploitation within two large multinational Pharmaceutical Companies in the UK. More recently his career has focused on commercial law activities, such as contract negotiation and intellectual property issues, and business development. He has completed a number of large scale grant applications for industrial research, and is author of numerous publications pertaining to pharmaceutical development, and is also a Fellow of the Royal Society of Chemistry.

Dr. Richard Toon is a chartered chemist who originally trained as a synthetic chemist and more recently trained in law. He has over 20 years of experience within pharmaceutical drug development including a number of years supervising ‘blue skies’ research projects for potential commercial exploitation within two large multinational Pharmaceutical Companies in the UK. More recently his career has focused on commercial law activities, such as contract negotiation and intellectual property issues, and business development. He has completed a number of large scale grant applications for industrial research, and is author of numerous publications pertaining to pharmaceutical development, and is also a Fellow of the Royal Society of Chemistry.

Board of Directors

Mr. Timothy Johnson

Mr. Johnson was elected as a director in July 2017. He is currently serving in executive positions in Diagnostax advisory, EQIQ and Protech Professional. Mr.Johnson received his first class Masters of Science in Mathematics and Physics from the University of Manchester, UK.

Dr. Salim Natha

Dr. Natha was elected as a director in July 2017. He is currently practicing as an Eye Surgeon in the UK National Health Service (NHS), and is the clinical lead for a retinopathy screening programme for over 20,000 diabetics in the Ashton, Wigan and Leigh region. He has published several articles in the medical literature and is a peer reviewer for the English National Diabetic Retinopathy Screening Programme. Dr. Natha graduated with honours from the University of Liverpool Medical School.

Mr. Thomas Moore

Mr. Moore was elected as a director in August 2017. He is currently working as a management consultant, having built up three decades of experience in the accountancy and consultancy fields at leading accountancy firms including Grant Thornton, KPMG and PricewaterhouseCoopers. He is a practicing Chartered Tax Adviser and earned his first class Bachelor of Arts in French and Russian from the University of Northumbria, UK.

Dr. Faz Chowdhury

Dr. Chowdhury has served as CEO and chair of the board of Nemaura Medical since formation in December 2013.  He is sole inventor on more than 50 granted and pending patents across over 15 technology platforms within the medical device and pharmaceutical sectors. He has authored Textbook Chapters on Nano-biosciences for Wiley and Elsevier, and serves on the Board of Medilink East Midlands, UK. Dr. Chowdhury trained as a pharmaceutical scientist, and holds a Masters in Microsystems and Nanotechnology from Cranfield University, UK, and Doctorate from the University of Oxford on nano-drug delivery.

Mr. Bashir Timol

Mr. Timol has served as member of the board of Nemaura Medical since formation in December 2013. He has co-founded, managed and funded several biotech and life science companies, and led the investment  consortium that provided capital for the initial two funding rounds for Nemaura Medical. Mr. Timol obtained his Bachelor of Arts degree in Economics from the University of Central Lancashire, UK.

Advisory Board

Fred Schaebsdau, MD, PhD

As Managing Director of privately held Weatherfield Management he negotiated and obtained the exclusive distribution rights in EMEA for UniStrip1™ generic blood glucose strips for the LifeScan® OneTouch® Ultra® family of blood glucose meters. Previously he was Global Head of Strategy and Business Development at Roche Diabetes Care during which he negotiated a CGM product development and distribution cooperation with Dexcom and the acquisition of Medingo insulin patch pumps. Prior to Roche, he was at Abbott Diabetes Care as Senior Director of Global Strategic Marketing and Strategic Planning and intensively involved in both the acquisition and merger of TheraSense and the FreeStyle Navigator® CGM. In 1993 he obtained an MBA from The Wharton School of the University of Pennsylvania and in 1986 a medical degree from the Justus Liebig University in Giessen, Germany.

Jeffrey Purvin

As CEO at Response Biomedical (TSX: RBM, OTCQB: RPBIF), Mr. Purvin directed the development, manufacturing and worldwide marketing of a variety of medical tests and test machines used by medical laboratories and government authorities. Prior to joining Response Biomedical, Mr. Purvin was the Chairman and CEO of Calibra Medical, Inc. At Calibra, he and his team developed and gained FDA clearance for a unique, small, wearable insulin delivery device. Johnson & Johnson acquired Calibra Medical in 2012. Prior to Calibra, Mr. Purvin was Chairman and CEO of Metrika, Inc. There, he and his team developed a handheld, point-of-care, semi-disposable, finger stick-based, HbA1c test which the company sold directly to physicians, consumers and other companies, worldwide. Bayer acquired Metrika in 2006.

Prior to Metrika, Mr. Purvin ran the Interventional Products Division of Datascope Corporation as its President. At Datascope, Mr. Purvin was responsible for marketing a large line of interventional cardiology and radiology devices to hospitals, worldwide.
Prior to Datascope, Mr. Purvin served as Vice President, General Manager, in GlaxoSmithKline’s $4B Consumer Healthcare division where he marketed scores of well-known, highly advertised consumer packaged goods.
Mr. Purvin started his career at Bristol-Myers Squibb, where he marketed both branded and generic pharmaceuticals and consumer products to both physicians and consumers.
Mr. Purvin served on the Board of Directors at Cardica, Inc [NASDQ: CRDC] for 5 years through 2014. Cardica markets a unique coronary bypass anastomosis connection device to cardiothoracic surgeons, worldwide, and is currently developing a unique, multi-staple-firing surgical stapler line. Mr. Purvin was Chair of Cardica’s Compensation Committee and was a member of its Audit and Finance Committees.
Mr. Purvin earned his B.A. from Brown University and his M.B.A from The Wharton School, University of Pennsylvania.

Dr. M. Begoña Delgado-Charro

Dr. M. Begoña Delgado-Charro graduated in Pharmacy (1986) and received her PhD in Pharmaceutical Technology from the University of Santiago de Compostela (1990, Spain).  She was a MEC-Fulbright fellow & visiting Assistant Professor at the School of Pharmacy, University of California, San Francisco (1991-1993); where she specialized in the iontophoretic delivery of peptides across the skin. Having served as an Assistant Professor at the University of Santiago de Compostela, and as Maître Assistant at the University of Geneva, Dr Delgado-Charro assumed her present position as Lecturer in Pharmaceutics in the Department of Pharmacy and Pharmacology, University of Bath, in 2004 and was promoted to Senior Lecturer (Associate Professor) in September 2008.

Dr. Delgado-Charro research has focused on transdermal and topical drug delivery by passive and iontophoretic means; on developing optimized methods to treat nail diseases such as onychomycosis and psoriasis, on non-invasive sampling for drug monitoring and pharmacokinetics, and on developing models to predict chemicals accumulation into the skin. Her work on drug delivery, bioequivalence of topicals and non-invasive sampling has been funded by the Parkinson’s Disease Society UK, the Medical Research Council, the Swiss National Foundation, the NHS-NIC, the FDA and several pharmaceutical companies.
Dr. Delgado-Charro is member of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT) where she is part of the Committee on “Alternative Sampling Methods in TDM”, the European Federation for Pharmaceutical Sciences (EUFEPS), the Academy of Pharmaceutical Scientists (APS), the Controlled Release Society (CRS), and of the “Centre for Mathematical Biology” at the University of Bath.
Dr. Delgado-Charro has supervised/co-supervised with success nine PhD students until now and currently supervises/co-supervises five PhD students. She has published 81 peer-reviewed articles in the scientific literature, 10 book chapters, 117 congress abstracts, and several patent applications. She was an invited speaker to the PPP, the Skin Forum, the AAPS and the IATDMCT meetings, as well as to the Gordon Conference on Barrier Function of Mammalian Skin.

Professor Richard Guy

Professor Richard Guy received an M.A. in Chemistry from Oxford University, and his Ph.D. in Pharmaceutical Chemistry from the University of London. He has held academic posts at the University of California, San Francisco and the University of Geneva. In 2004, he joined the University of Bath as Professor of Pharmaceutical Sciences in the Department of Pharmacy & Pharmacology. Dr. Guy is an elected fellow of the Academy of Pharmaceutical Scientists, Great Britain, the Royal Society of Chemistry, the Controlled Release Society, the American Association of Pharmaceutical Scientists, and the American Association for the Advancement of Science.

Dr. Guy’s research focuses on skin barrier function characterization, transdermal drug delivery, enhancement of percutaneous absorption, iontophoresis, noninvasive biosensing, and the prediction and assessment of skin penetration and topical bioavailability.
Dr. Guy has published 350+ peer-reviewed articles and over 70 book chapters. He has co-authored one book and co-edited 7 others. He is also co-inventor of 12 patents. Specific ongoing projects include: measurement of the skin’s biomechanical properties at the nanoscale using atomic force microscopy; the potential of polymeric film-forming systems as sustained release platforms for topical drugs; determination of the disposition of drug and formulation excipients (including nanoparticles) post-application to the skin using coherent Raman scattering and confocal microscopy; development of an integrated iontophoretic delivery system for buprenorphine and naltrexone to treat polydrug abuse; examination of a graphene-based biosensor for noninvasive, transdermal glucose monitoring; development of in vitro – in vivo  correlations with which to assess the bio(in)equivalence of topical drug products; and derivation and evaluation of predictive models of percutaneous penetration for pharmaceutical and cosmetic ‘actives’, and for potentially toxic chemicals, which come into contact with skin.

Dr. Hubert Penninckx

Dr. Hubert Penninckx is Consultant Endocrinologist-Diabetologist at the American Hospital Dubai (since 2006) and Director of the Diabetes Center. From 1980-2002 he was an Endocrinologist, and from 1989 Chief of the Internal Medicine Department, at the St Jozef Hospital in Vilvoorde Belgium. From 2002-2005 he was Head of the Endocrinology Department and Head of the Diabetes Team at A.Z.Jan Portaels Hospital in the same city.

After graduating as M.D. in Medicine in 1975 Dr. Penninckx got the License of Specialist in Internal Medicine and Endocrinology in 1980 from University KUL in Leuven Belgium. He obtained official general recognition by the Belgium Ministry of Health of the specialty license Endocrinology-Diabetology. He is a Fellow of EASD and the European Endocrine Society.

Dr. Penninckx was professor at the Artevelde High School in Gent, Belgium(1999-2003), Member of the Ethics Committee and Consultant at the University Hospital Melsbroek for more than 15 years. He was also Medical Advisor for the Belgian Diabetes Club and President of the Medical Board at the St.Jozefskliniek in Vilvoorde for 8 years and a member of the Advisory Board for the monthly Journal ‘Bijblijven’, publication of Bohn-Sholtema in the Netherlands. Dr. Penninckx is also an active Endocrinology ‘expert’ in the Belgian Courts. His publications are numerous with over 1000 lectures delivered on Diabetes. His involvement in different European and US Clinical trials include:

– 3a diabetic poly-neuropathy with aldose reductase inhibitor sorbinil
– 3a diabetic micro-albuminuria with aldose reductase inhibitor sorbinil
– 3b erectile dysfunction trial with taldafil
– 2b micro-albuminuria trial with tolrestat
– personal experimental work about insulin resistance and lithium(Novo price young investigators)
– 3a diabetic neuropathy trial with rNGF injections
– 3a trial with detemir in type 1 diabetes
– personal experimental work about correlation micro-albuminuria and erectile dysfunction, and etiology erectile dysfunction  in type 1 diabetes (IDF Helsinki 1997)
– AGE reader trial with GLP1-analogs on cardio-vascular risks in type 2 diabetes

Dr. Penninckx is also a member of the Advisory Board for Pharmaceutical Companies including Sanofi, Novo-Nordisk, Ely-Lily, and Astra-Zeneca.

Stay informed

  • This field is for validation purposes and should be left unchanged.